Lower urinary tract (LUT) dysfunction is common in patients with multiple sclerosis and is a
major negative influence on the quality of life of these patients. The most commonly reported …

Purpose: Overactive bladder affects 12% to 17% of the general population and almost a
third experience urinary incontinence, which may severely impact health related quality of …

Background Overactive bladder (OAB) syndrome with urinary incontinence (UI) is prevalent
in the population and impairs health-related quality of life (HRQOL). Objective To assess the …

CONTEXT: The European Association of Urology (EAU) guidelines on urinary incontinence
published in March 2012 have been rewritten based on an independent systematic review …

Abstract Context Botulinum toxin A (BoNTA) has received regulatory approval for use in
neurogenic detrusor overactivity (NDO) and overactive bladder (OAB), but it remains …

Parkinson's disease (PD) is a common neurodegenerative disorder, and lower urinary tract
(LUT) dysfunction is one of the most common autonomic disorders with an estimated …

Purpose: These are the final results of the prospective, multicenter, long-term (3.5-year)
study of the efficacy/safety of onabotulinumtoxinA for overactive bladder syndrome. Materials …

BACKGROUND: Efficacy and safety of botulinum toxin type A (BoNTA) injection is supported
by level 1 evidence, but data regarding repeated injections are limited in patients with …

What's known on the subject? and What does the study add? It is known that intravesical
botulinum toxin (BT) is an effective treatment for overactive bladder, especially in the …

Overactive bladder syndrome is a chronic, disabling condition with physical, psychological
and social consequences that significantly affects the quality of life of millions of patients …